Profile data is unavailable for this security.
About the company
genedrive plc is a United Kingdom-based pharmacogenetic testing company. The Company is engaged in developing and commercializing a rapid, versatile, simple to use and robust point-of-need pharmacogenetic platform for the diagnosis of genetic variations. The Company’s products include Genedrive MT-RNR1 ID Kit, Genedrive System, and Genedrive CYP2C19 ID Kit. The Company’s flagship product Genedrive MT-RNR1 ID Kit is a single-use disposable cartridge that circumvents the requirement for cold chain logistics by providing temperature stable reagent test kits for use on their proprietary test platform. The Genedrive System is a rapid thermocycler and signal detection system, enabling PCR and isothermal based amplification techniques. It is a semi- automated system used for qualitative in vitro molecular diagnostic tests. Its Genedrive CYP2C19 ID Kit Molecular point-of-care test for rapid CYP2C19 genotyping in time-critical emergency care settings.
- Revenue in GBP (TTM)954.00k
- Net income in GBP-5.23m
- Incorporated2007
- Employees43.00
- LocationGenedrive PLC48 Grafton StreetMANCHESTER M13 9XXUnited KingdomGBR
- Phone+44 161 989 0245
- Fax+44 161 989 0262
- Websitehttps://www.genedriveplc.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genincode PLC | 2.91m | -4.97m | 3.30m | 36.00 | -- | 1.24 | -- | 1.13 | -0.0232 | -0.0232 | 0.0137 | 0.0093 | 0.6562 | 15.74 | 2.87 | 80,944.45 | -111.87 | -- | -164.53 | -- | 53.02 | -- | -170.49 | -- | 2.73 | -10.96 | 0.0669 | -- | 25.05 | -- | 36.80 | -- | -- | -- |
| Surgical Innovations Group Plc | 11.92m | -1.44m | 4.20m | 88.00 | -- | 0.4903 | -- | 0.3523 | -0.0015 | -0.0015 | 0.0128 | 0.0092 | 0.9314 | 2.91 | 4.72 | 135,397.70 | -11.22 | -7.76 | -14.17 | -9.60 | 27.89 | 29.97 | -12.04 | -11.66 | 0.9524 | 8.46 | 0.0987 | -- | -0.5743 | 2.16 | -281.73 | -- | -8.28 | -- |
| Cambridge Nutritional Sciences PLC | 8.06m | 1.37m | 4.76m | 84.00 | 3.50 | 0.4305 | 2.38 | 0.5905 | 0.0057 | 0.0057 | 0.0338 | 0.0465 | 0.6153 | 3.59 | 3.57 | 95,940.48 | 10.42 | -3.22 | 11.69 | -3.67 | 66.44 | 58.85 | 16.94 | -7.21 | 3.79 | -- | 0.021 | -- | -14.77 | -3.23 | 577.44 | -- | -29.24 | -- |
| Feedback plc | 885.62k | -7.32m | 4.89m | 28.00 | -- | 0.7925 | -- | 5.52 | -0.2618 | -0.2618 | 0.0309 | 0.1407 | 0.1174 | -- | 9.83 | 31,629.29 | -96.97 | -38.54 | -105.98 | -41.65 | 87.92 | 90.05 | -826.25 | -435.27 | -- | -- | 0.00 | -- | -25.05 | 14.50 | -121.85 | -- | -1.14 | -- |
| Proteome Sciences plc | 4.53m | -3.33m | 6.05m | 36.00 | -- | -- | -- | 1.34 | -0.0113 | -0.0113 | 0.0153 | -0.0291 | 0.5087 | 5.92 | 5.75 | 125,750.00 | -37.44 | -8.02 | -- | -- | 17.43 | 45.80 | -73.60 | -15.07 | 0.0774 | -2.51 | 2.26 | -- | -2.80 | 0.9731 | -39.42 | -- | 31.03 | -- |
| Rua Life Sciences PLC | 5.17m | -850.00k | 9.00m | 33.00 | -- | 1.26 | -- | 1.74 | -0.0137 | -0.0137 | 0.0832 | 0.1151 | 0.5459 | 1.18 | 6.23 | -- | -9.18 | -- | -10.42 | -- | 77.10 | -- | -16.82 | -- | 3.87 | -- | 0.0995 | -- | -- | -- | -- | -- | -- | -- |
| Genedrive PLC | 954.00k | -5.23m | 10.81m | 43.00 | -- | 4.56 | -- | 11.33 | -0.0093 | -0.0093 | 0.0017 | 0.0023 | 0.1984 | -- | 1.80 | 22,186.05 | -108.81 | -77.52 | -153.92 | -106.30 | -- | -- | -548.32 | -1,016.12 | 1.64 | -- | 0.00 | -- | 90.42 | -2.07 | 26.06 | -- | -10.48 | -- |
| Verici DX PLC | 1.40m | -5.56m | 10.91m | 15.00 | -- | 0.9642 | -- | 7.81 | -0.0229 | -0.0229 | 0.0058 | 0.0075 | 0.2298 | -- | 1.67 | 77,631.66 | -91.48 | -- | -119.40 | -- | 81.60 | -- | -398.12 | -- | -- | -- | 0.102 | -- | 229.62 | -- | 32.75 | -- | -- | -- |
| Cellbxhealth PLC | 2.62m | -15.78m | 11.96m | 119.00 | -- | 0.2897 | -- | 4.56 | -0.0489 | -0.0489 | 0.0081 | 0.0362 | 0.1028 | 0.5939 | 1.46 | 22,050.42 | -61.80 | -41.90 | -72.78 | -46.81 | 62.27 | 18.55 | -601.37 | -1,051.13 | 2.63 | -470.57 | 0.2387 | -- | 30.92 | -- | 29.34 | -- | -- | -- |
| Abingdon Health PLC | 8.43m | -3.42m | 15.06m | 121.00 | -- | 2.19 | -- | 1.79 | -0.0176 | -0.0176 | 0.0435 | 0.0274 | 1.17 | 9.71 | 3.87 | 69,661.16 | -47.42 | -54.04 | -70.70 | -85.91 | 44.32 | 30.37 | -40.51 | -110.07 | 1.58 | -- | 0.1625 | -- | 37.39 | 9.99 | -168.69 | -- | -26.92 | -- |
| Inspiration Healthcare Group PLC | 45.20m | -11.44m | 15.24m | 214.00 | -- | 0.9312 | -- | 0.3372 | -0.1275 | -0.1275 | 0.5038 | 0.1826 | 1.03 | 2.00 | 5.91 | 211,215.00 | -25.96 | -6.05 | -33.03 | -7.45 | 44.39 | 46.62 | -25.32 | -7.01 | 1.11 | 2.42 | 0.441 | -- | 1.65 | 16.56 | -148.04 | -- | 39.05 | -- |
| Renalytix PLC | 2.19m | -14.90m | 25.20m | 45.00 | -- | -- | -- | 11.50 | -0.0594 | -0.0594 | 0.008 | -0.0154 | 0.4547 | 7.64 | 4.54 | -- | -309.18 | -83.70 | -- | -107.25 | 40.00 | 28.27 | -680.00 | -1,519.31 | 1.17 | -24.57 | 6.38 | -- | 31.06 | -- | 55.14 | -- | -- | -- |
| Aptamer Group PLC | 1.20m | -2.42m | 25.62m | 31.00 | -- | 13.69 | -- | 21.30 | -0.0014 | -0.0014 | 0.0007 | 0.0007 | 0.4294 | 6.27 | 4.35 | 38,806.45 | -86.53 | -- | -154.00 | -- | 48.13 | -- | -201.50 | -- | 1.48 | -84.63 | 0.2622 | -- | 39.88 | -- | 18.05 | -- | -- | -- |
Data as of Feb 10 2026. Currency figures normalised to Genedrive PLC's reporting currency: UK Pound GBX
7.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Peel Hunt LLPas of 24 Jun 2024 | 54.27m | 5.27% |
| Hargreaves Lansdown Fund Managers Ltd.as of 01 Jan 2022 | 4.36m | 0.42% |
| Jarvis Investment Management Ltd.as of 14 Jun 2023 | 2.95m | 0.29% |
| IG Markets Ltd.as of 01 Jan 2022 | 2.74m | 0.27% |
| Rathbones Investment Management Ltd.as of 01 Jan 2022 | 2.35m | 0.23% |
| HSBC Global Asset Management (UK) Ltd.as of 01 Jan 2022 | 2.21m | 0.21% |
| BGF Investment Management Ltd.as of 05 Feb 2021 | 1.91m | 0.19% |
| Walker Crips Investment Management Ltd.as of 01 Jan 2022 | 1.90m | 0.18% |
| M&G Investment Management Ltd.as of 05 Feb 2020 | 1.76m | 0.17% |
| Unicorn Asset Management Ltd.as of 31 Jan 2026 | 1.15m | 0.11% |
More ▼
Data from 31 Mar 2025 - 02 Feb 2026Source: FactSet Research Systems Inc.
